John Sourbeer
Stock Analyst at UBS
(0.71)
# 4,014
Out of 5,058 analysts
42
Total ratings
33.33%
Success rate
-17.62%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $8.46 | +47.75% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $120.12 | -0.10% | 4 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $257.90 | +37.65% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $44.43 | +12.54% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $158.81 | +51.12% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $21.34 | +10.12% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $20.99 | +114.39% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.76 | +13.64% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $592.18 | -18.94% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $43.39 | +135.08% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $15.65 | +219.49% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $126.15 | +1.47% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $8.46
Upside: +47.75%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $120.12
Upside: -0.10%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $257.90
Upside: +37.65%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $44.43
Upside: +12.54%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $158.81
Upside: +51.12%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $21.34
Upside: +10.12%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $20.99
Upside: +114.39%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.76
Upside: +13.64%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $592.18
Upside: -18.94%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $43.39
Upside: +135.08%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $15.65
Upside: +219.49%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $126.15
Upside: +1.47%